ArticleNeuro-oncology advances2025
Current understanding of the role of DNA methylation in pituitary neuroendocrine tumors.
Article in Neuro-oncology advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- DNA methylation as a predictor of pituitary neuroendocrine tumour behaviour: A systematic review.Journal of neuroendocrinology · 2026Pooled it
- Association between preoperative MRI radiomic features and methylation-defined phenotypes in non-functioning pituitary adenomas.Pituitary · 2026Article
- Exploring epigenome-proteome interactions underlying post-surgical progression of non-functioning pituitary adenomas using hypernetwork modelling.Journal of translational medicine · 2026Article
- The role of methylation in pituitary neuroendocrine tumors current insights and emerging perspectives.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pituitary neuroendocrine tumors (PitNETs) are unusual among neoplasms in that sporadic tumors are not typically associated with genetic mutations. Instead, epigenetics, a non-mutational process by which gene expression is modified via a variety of mechanisms, may be a driving factor in PitNET growth and behavior. DNA methylation is one of the most well-understood forms of epigenetic modification. Research on DNA methylation profiles of PitNETs has identified a large number of genes silenced or upregulated by DNA methylation, particularly when methylated at CpG islands of gene promoter regions. Global patterns of DNA methylation may provide valuable insight into the origins of pituitary adenoma subtypes, assist with PitNet diagnostics, and have been found to correspond to the current World Health Organization classification of PitNETs based on transcription factor lineage. Analysis of differentially methylated regions of individual genes may have prognostic value as well as guide research toward nonsurgical therapeutic strategies. Pituitary epigenetics and DNA methylation analysis are rapidly growing areas of interest with the potential to shape the future of pituitary tumor diagnostics and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.